Published in Am J Clin Pathol on January 01, 2003
Fetal-maternal hemorrhage quantitation by flow cytometry. Am J Clin Pathol (2004) 0.75
Assessment of feto-maternal hemorrhage among rhesus D negative pregnant mothers using the kleihauer-betke test (KBT) and flow cytometry (FCM) in Addis Ababa, Ethiopia. BMC Pregnancy Childbirth (2014) 0.75
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood (2011) 6.50
Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.88
Systematic overview of warfarin and its drug and food interactions. Arch Intern Med (2005) 5.86
Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med (2011) 4.59
The vexing problem of guidelines and conflict of interest: a potential solution. Ann Intern Med (2010) 3.47
Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med (2013) 3.40
Acute kidney injury after cardiac surgery: focus on modifiable risk factors. Circulation (2009) 3.10
Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost (2011) 2.75
A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med (2013) 2.68
Indications, complications, and management of inferior vena cava filters: the experience in 952 patients at an academic hospital with a level I trauma center. JAMA Intern Med (2013) 2.52
Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med (2007) 2.50
Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 2.50
Antiphospholipid syndrome. Lancet (2010) 2.47
Predicting deep venous thrombosis in pregnancy: out in "LEFt" field? Ann Intern Med (2009) 2.26
Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes. Chest (2013) 2.24
Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation (2012) 2.16
Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med (2005) 1.87
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol (2012) 1.85
Fresh frozen plasma transfusion in critically ill patients. Crit Care Med (2007) 1.81
Thrombopoietin-receptor agonists for primary immune thrombocytopenia. N Engl J Med (2011) 1.78
Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ (2008) 1.71
Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood (2004) 1.67
Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med (2002) 1.55
A red blood cell agglutination D-dimer test to exclude deep venous thrombosis in pregnancy. Ann Intern Med (2007) 1.53
Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: a pilot study. J Crit Care (2005) 1.50
Non-OO blood type influences the risk of recurrent venous thromboembolism. A cohort study. Thromb Haemost (2013) 1.47
Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. Anesthesiology (2014) 1.47
Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest (2005) 1.41
Postpartum management of women at increased risk of thrombosis--results of a Canadian pilot survey. J Rheumatol (2006) 1.40
Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum. Ann Pharmacother (2008) 1.32
Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. Arch Intern Med (2008) 1.28
A diagnostic strategy involving a quantitative latex D-dimer assay reliably excludes deep venous thrombosis. Ann Intern Med (2003) 1.21
Post-thrombotic syndrome in children: a systematic review of frequency of occurrence, validity of outcome measures, and prognostic factors. Haematologica (2010) 1.20
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment. Am J Hematol (2009) 1.18
The risk of hemorrhage among patients with warfarin-associated coagulopathy. J Am Coll Cardiol (2006) 1.16
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. Am J Hematol (2009) 1.11
Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis. Blood (2006) 1.10
JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood (2009) 1.09
Outcome of pregnancy in homozygous sickle cell disease. Obstet Gynecol (2004) 1.08
Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists: a multi-centre, retrospective cohort study. Thromb Haemost (2009) 1.07
Comment on: editorial by Husted et al. "Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel". (Thromb Haemost 2014; 111: 781-782). Thromb Haemost (2014) 1.07
Detecting myocardial infarction in critical illness using screening troponin measurements and ECG recordings. Crit Care (2008) 1.03
Incidence of venous thromboembolism in patients undergoing thoracotomy for lung cancer. J Thorac Cardiovasc Surg (2008) 1.00
Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review. J Crit Care (2009) 1.00
Safety of thrombolysis in cerebral venous thrombosis. A systematic review of the literature. Thromb Haemost (2010) 0.97
Reversal of target-specific oral anticoagulants. J Thromb Thrombolysis (2013) 0.96
Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. Crit Care (2008) 0.96
Tailoring warfarin induction doses to reflect individual and disease-specific factors. Am J Med (2005) 0.95
Has the incidence of deep vein thrombosis in patients undergoing total hip/knee arthroplasty changed over time? A systematic review of randomized controlled trials. Thromb Res (2008) 0.93
Development of North American consensus guidelines for medical laboratories that perform and interpret platelet function testing using light transmission aggregometry. Am J Clin Pathol (2010) 0.92
Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis. Pharmacoeconomics (2006) 0.90
Evidence and clinical judgment: vena cava filters. Thromb Haemost (2014) 0.88
Direct thrombin inhibitors. Thromb Res (2002) 0.88
Prediction scores do not correlate with clinically adjudicated categories of pulmonary embolism in critically ill patients. Can Respir J (2013) 0.87
Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure. J Thromb Thrombolysis (2011) 0.87
Clinically important deep vein thrombosis in the intensive care unit: a survey of intensivists. Crit Care (2004) 0.86
PROphylaxis for ThromboEmbolism in Critical Care Trial protocol and analysis plan. J Crit Care (2011) 0.85
Targeting anemia with erythropoietin during critical illness. N Engl J Med (2007) 0.85
Impact of thromboprophylaxis guidelines on clinical outcomes following total hip and total knee replacement. Thromb Res (2012) 0.85
Good practice guidelines for laboratory investigation of hemoglobinopathies. Lab Hematol (2003) 0.85
The "parallel-cohort RCT": Novel design aspects and application in the Kids-DOTT trial of pediatric venous thromboembolism. Contemp Clin Trials (2009) 0.85
Interlaboratory variation in heparin monitoring: Lessons from the Quality Management Program of Ontario coagulation surveys. Thromb Haemost (2010) 0.84
Practice patterns for deep vein thrombosis prophylaxis in minimal-access surgery. Can J Surg (2006) 0.84
Red blood cell transfusion and increased length of storage are not associated with deep vein thrombosis in medical and surgical critically ill patients: a prospective observational cohort study. Crit Care (2011) 0.84
The incidence and impact of lupus anticoagulants among patients in the intensive care unit. Saudi Med J (2005) 0.83
Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thromb Haemost (2016) 0.83
Are brand-name and generic warfarin interchangeable? A survey of Ontario patients and physicians. Can J Clin Pharmacol (2005) 0.83
Thromboprophylaxis patterns and determinants in critically ill patients: a multicenter audit. Crit Care (2014) 0.83
Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Data from the REVERSE cohort study. Thromb Haemost (2010) 0.83
Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. Br J Haematol (2005) 0.83
Treatment of warfarin-associated coagulopathy with vitamin K. Expert Rev Hematol (2011) 0.82
Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis. Intensive Care Med (2013) 0.82
Practical aspects of new oral anticoagulant use in atrial fibrillation. Pol Arch Med Wewn (2014) 0.81
Acute effects of nicotine on serum glucose insulin growth hormone and cortisol in healthy smokers. Metabolism (2004) 0.81
Thrombopoietin receptor agonists in primary immune thrombocytopenia. Semin Hematol (2013) 0.81
Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil. J Thromb Thrombolysis (2011) 0.79
Antiphospholipid antibodies in critical illness. Crit Care Med (2010) 0.79
Effect of chronic kidney disease on red blood cell rheology. Clin Hemorheol Microcirc (2006) 0.79
Practice guidelines on the reporting of smudge cells in the white blood cell differential count. Arch Pathol Lab Med (2003) 0.78
In-house calibration of the international sensitivity index or calibration curve for determination of the international normalized ratio. Arch Pathol Lab Med (2004) 0.78
Low prevalence of JAK2 V617F mutation in patients with first unprovoked venous thromboembolism. Br J Haematol (2011) 0.78
Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients. Medicine (Baltimore) (2015) 0.78
Treatment with novel oral anticoagulants: indications, efficacy and risks. Curr Opin Hematol (2013) 0.78
The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis. Blood Coagul Fibrinolysis (2016) 0.78
Dabigatran-induced acute hepatitis. Clin Appl Thromb Hemost (2012) 0.78